Chi-Med’s Surufatinib Secures Approval in China
Chi-Med’s surufatinib has been approved by China’s National Medical Products Administration (NMPA) for treating nonpancreatic neuroendocrine tumors.
The novel oral tyrosine kinase inhibitor, which reduced the risk of progression or death by 67 percent in the company’s phase 3 trial, will be branded as Sulanda in China.
The approval is Chi-Med’s first in China for an oncology drug it developed on its own. Elunate (fruquintinib), which it co-developed with Eli Lilly, previously received NMPA approval for treating metastatic colorectal cancer.